- Home
- VRCA vs FORA Comparison
VRCA vs FORA Comparison
Compare VRCA & FORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | FORA |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 66.2M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VRCA | FORA |
|---|---|---|
| Price | $6.17 | $2.04 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 122.3K | 15.0K |
| Earning Date | 06-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,577,000.00 | $20,153,263.00 |
| Revenue This Year | $372.93 | $51.82 |
| Revenue Next Year | N/A | $7.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $0.39 | $1.64 |
| 52 Week High | $9.82 | $2.71 |
Technical Indicators
Market Signals| Indicator | VRCA | FORA |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 37.28 |
| Support Level | $5.22 | $2.05 |
| Resistance Level | $6.44 | $2.12 |
| Average True Range (ATR) | 0.46 | 0.02 |
| MACD | 0.15 | -0.00 |
| Stochastic Oscillator | 69.87 | 16.67 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.